LoginSignup
Corcept logo

Corcept

Stock
Stock
ISIN: US2183521028
Ticker: CORT
US2183521028
CORT

Price

Price

Frequently asked questions

What is Corcept's market capitalization?

The market capitalization of Corcept is $5.86B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Corcept's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Corcept is 44.04. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Corcept?

Corcept's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.27. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Corcept's stock?

Currently, 5 analysts cover Corcept's stock, with a consensus target price of $49.70. Analyst ratings provide insights into the stock's expected performance.

What is Corcept's revenue over the trailing twelve months?

Over the trailing twelve months, Corcept reported a revenue of $628.56M.

What is the EBITDA for Corcept?

Corcept's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $144.50M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Corcept?

Corcept has a free cash flow of $143.02M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Corcept's stock?

The 5-year beta for Corcept is 0.50. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Corcept have, and what sector and industry does it belong to?

Corcept employs approximately 352 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Corcept's shares?

The free float of Corcept is 92.70M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $5.86B

5Y beta

 0.50

EPS (TTM)

 $1.27

Free Float

 92.70M

P/E ratio (TTM)

 44.04

Revenue (TTM)

 $628.56M

EBITDA (TTM)

 $144.50M

Free Cashflow (TTM)

 $143.02M

Pricing

1D span
$55.91$56.05
52W span
$20.84$61.66

Analyst Ratings

The price target is $49.70 and the stock is covered by 5 analysts.

Buy

5

Hold

0

Sell

0

Information

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

352

Biotechnology & Drugs

Health Care

Identifier

ISIN

US2183521028

Primary Ticker

CORT

Knockouts

Join the conversation
Sign upLogin